Quantifying the Impact of Dropout in a Clinical Trial Simulation

Why quantify dropout in a trial simulation?

A trial simulation can show not only what an analysis would estimate if all outcomes were observed, but also how the planned trial might behave when participants discontinue or miss endpoint assessments. The distinction matters: fewer observed outcomes generally reduce precision, while selective missingness can also shift the estimated treatment effect. A simulation that varies only the dropout rate, while silently holding its mechanism fixed, can therefore give an incomplete picture.

The objective here is to compare prespecified retention assumptions and dropout mechanisms in a hypothetical randomized trial. The simulation should represent the trial’s outcome process, dropout process, and planned analysis; it should then summarize bias, precision, and the probability of meeting a defined success criterion. Those summaries describe performance under the assumptions encoded in the simulation, not guaranteed properties of a future trial.

Define the estimand, dropout mechanism, and success rule

Three standard mechanism labels are useful. Under missing completely at random (MCAR), the probability an endpoint is observed does not depend on the participant’s outcomes or measured covariates. Under missing at random (MAR), that probability may depend on observed information, such as baseline severity or previously observed outcomes, but not on the missing endpoint after conditioning on the observed information. Under missing not at random (MNAR), missingness still depends on the unobserved endpoint after conditioning on the observed information. These labels concern the conditional dropout process; they cannot usually be verified from observed data alone.

For a concrete comparison, consider a two-arm trial with a continuous endpoint at week 12. The primary analysis is a two-sided test of no treatment difference at \(\alpha=0.05\), and the trial is called statistically successful when its p-value is below 0.05. This is one possible success rule, not a universal definition of clinical success. A clinical decision may also require a minimum effect or account for safety and other evidence.

The primary summary of estimation performance is bias: the average estimated effect across simulated trials minus the true effect specified by the data-generating model. Precision can be summarized by the standard deviation of estimates across trials or by the average standard error reported by the analysis. These are related but not interchangeable: the first describes variation of estimates across repeated simulated trials, while the second is calculated within each trial.

Build a simulation that isolates dropout effects

Specify the trial before comparing scenarios. A simple starting model is a randomized, balanced trial in which the endpoint is generated as a treatment effect plus a baseline prognostic contribution and random error. For example, a normally distributed endpoint can be represented as \(Y_i=\mu+\Delta A_i+\beta B_i+\epsilon_i\), where \(A_i\) is randomized assignment, \(B_i\) is a baseline variable, and \(\epsilon_i\) is random error. The simulated population distribution of \(B_i\), the error variance, treatment effect, sample size, and dropout rule must all be stated.

The simulation should also specify how missing outcomes are handled. A complete-case comparison uses only participants with observed endpoints. A likelihood-based repeated-measures analysis or multiple imputation can use observed outcome history under suitable modeling assumptions; MAR alone does not guarantee that a particular fitted model is correct. Inverse probability weighting instead reweights observed participants by their modeled probability of remaining observed, and relies on a correctly specified observation model and adequate probabilities of observation. Under MNAR, these methods generally need additional assumptions about the unobserved outcomes; an analysis that is valid under MAR is not automatically valid under MNAR.

For fair comparisons, hold the data-generating model, sample size, randomization, analysis, and success criterion fixed while changing the dropout assumptions of interest. If several elements change at once, the cause of a difference in results becomes harder to interpret. The simulation should also be checked for implementation errors: in a no-dropout scenario, for instance, it should recover the expected behavior of the specified analysis within Monte Carlo variation.

Worked examples: rate, mechanism, and trial success

Justifying the MCAR precision comparison

The precision calculation in the first example follows directly from independence. If the observed outcomes in arm \(a\) have variance \(\sigma^2\) and there are \(n_a\) observed participants, the variance of their sample mean is \(\sigma^2/n_a\). For independent randomized arms, the variance of the difference of sample means is the sum of those variances. Therefore:

Under MCAR, the observed participants are, in expectation, representative of their randomized arms with respect to the endpoint. The expected arm means therefore remain the population arm means, while smaller \(n_1\) and \(n_0\) increase the variance in the expression above. This justification depends on independent participants, finite endpoint variance, and the stated MCAR assumption; it does not establish unbiasedness under outcome-dependent dropout.

Compare scenarios and diagnose failure modes

A useful simulation reports more than the proportion of trials declared successful. It should show, by dropout scenario, the mean estimated treatment effect, its bias relative to the generating value, the standard deviation of estimates across trials, average estimated standard error, confidence-interval coverage when relevant, and the success proportion. A compact scenario table makes the distinct roles of mechanism and rate visible.

Diagnostics begin with the simulated data and the analysis output. Check that intended dropout rates are achieved overall and by arm, that dropout probabilities remain within 0 and 1, and that the simulated reasons and timing of discontinuation are coherent with the scenario. Compare baseline covariates and observed outcome histories between retained and discontinued participants. Differences can reveal selection patterns, although their absence cannot establish MCAR or rule out MNAR, because the missing endpoint itself is unavailable.

Also inspect estimates and standard errors across replicates. A growing standard deviation of estimates with higher MCAR dropout is expected. A systematic difference between the average estimate and the known generating effect signals bias under that scenario or a problem in the implementation. Poor confidence-interval coverage can indicate bias, underestimated uncertainty, or both. If a fitted model fails to converge frequently, or weights become extreme, the reported success rate may reflect unstable analysis behavior as well as the intended dropout effect.

The main alternatives answer different questions. A complete-case analysis is simple and may be appropriate under MCAR for the stated endpoint, but it discards observed histories and is not generally protected from selection bias. A likelihood-based longitudinal analysis or multiple imputation can use observed outcomes under MAR when the model is adequately specified and relevant observed predictors are included. Inverse probability weighting targets a similar issue through modeled observation probabilities, but can be unstable when some participants have very low probabilities of remaining observed. For MNAR, sensitivity analyses vary assumptions about outcomes that would have been observed; they do not identify the missing outcomes from the observed data alone.

A limitation of any simulation is that its conclusions are conditional on the data-generating assumptions. Real dropout can have multiple causes, vary over time, differ between arms, and depend on evolving health or treatment experience. A single dropout percentage cannot capture these features. A practical analysis therefore compares plausible mechanisms and rates, checks implementation under simpler scenarios, and reports which conclusions remain stable across assumptions. This quantifies the consequences of assumptions; it does not prove which mechanism will occur.

Common pitfall